Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France | PLOS ONE
Should We Prevent Off-Label Drug Prescriptions? Empirical Evidence from France”
Vaccines | Free Full-Text | Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
Nouvelle indemnisation transparente pour les médicaments soumis à ordonnance | Communauté d'achat HSK SA
Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France | PLOS ONE
Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program - ScienceDirect
Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France | PLOS ONE
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France - Erin Johansson, Anders Gustavsson, Carolin Miltenburger, Korinna Karampampa, Lucien Rumbach, Karin Rérat, Celine Thonnelier, 2012
Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program - ScienceDirect
Full article: A comparative public health and budget impact analysis of pneumococcal vaccines: The French case
PowerPoint 簡報
utilisation des médicaments dans les maisons de soins - KCE
PDF) Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: Results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)
PDF) The economic burden of urinary tract infections in women visiting general practices in France: A cross-sectional survey
POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure | SpringerLink
Patient access to orphan drugs in France | Orphanet Journal of Rare Diseases | Full Text
L/6589/Add.2 Addendum couvert du document L/6589/Add.1. La traduction non officielle de cette en el documents L/6589/Add.l. La t
Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System | Health Affairs
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) • The Journal of Prevention of Alzheimer's Disease
Prix des médicaments - Comparaison avec l'étranger 2011, Conférence de presse santésuisse, interpharma et vips 20
8 remèdes au prix élevé des médicaments | Paperjam News
PandaLab | La messagerie médicale au coeur de votre pratique
Modèle tarifaire équitable | Zur Rose
La base de données médicaments Thériaque - CNHIM
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France - Erin Johansson, Anders Gustavsson, Carolin Miltenburger, Korinna Karampampa, Lucien Rumbach, Karin Rérat, Celine Thonnelier, 2012
